Alcobra seeks FDA's IND approval for Metadoxine extended-release to treat ADHD

Israeli biopharmaceutical company Alcobra has filed an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to start a Phase III clinical trial with its proprietary drug candidate MG01CI (Metadoxine extended-release…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news